Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by santi69on Jun 12, 2013 3:05pm
206 Views
Post# 21516579

RE: Question about the NOX deposit.

RE: Question about the NOX deposit.

It is too early to answer your question at this time. From the 4 April 2013 news release the company offered the following for some of the drill areas:

 

"We are very pleased with these results, they are in line with what we expected in the North zone" said Michael Iverson, President and CEO of NioGold. He added, "Our investigation of this satellite zone of the Norlartic deposit is part of our goal to develop the huge potential of the Marban Block. The results to date indicate that the North zone as well as the Norlartic and Kierens deposits may be amendable to open pit mining, as widths and grades are similar to the Marban deposit which has been modeled for open pit extraction".

The North zone was drilled between December 7th, 2012 and February 21st, 2013 with one drill. Drilling comprised 4,394.6 meters in 18 holes (one an extension of a 2006 hole). The campaign then continued on the Kierens deposit which was completed March 22nd, 2013. This program utilized up to four drills operating on ice bridges. Results from this program will be reported when received and compiled.

<< Previous
Bullboard Posts
Next >>